Introduction
============

Chronic noncancer pain (CNCP) has been reported by one in five Canadians,[@b1-jpr-7-163],[@b2-jpr-7-163] with similar prevalence around the world.[@b3-jpr-7-163],[@b4-jpr-7-163] CNCP is a source of personal suffering and constitutes a major economic burden for our society.[@b2-jpr-7-163],[@b5-jpr-7-163]--[@b7-jpr-7-163] Like other chronic diseases, chronic pain is managed essentially in primary care, where it accounts for about 20% of all patients seen.[@b5-jpr-7-163],[@b8-jpr-7-163] In a US nationwide telephone survey, only 5% of these patients reported having ever consulted a pain specialist.[@b9-jpr-7-163] CNCP is often poorly managed.[@b1-jpr-7-163],[@b10-jpr-7-163] An American Pain Society survey revealed that more than 40% of patients with chronic pain suffered from uncontrolled pain.[@b10-jpr-7-163] Pharmacotherapy is an important component of pain treatment. Pain-relievers top the list of classes of therapeutic drugs prescribed during visits to physicians' offices and emergency rooms.[@b11-jpr-7-163]

Patient satisfaction is important in the evaluation of CNCP management and, as in other diseases, is associated with treatment effectiveness.[@b12-jpr-7-163],[@b13-jpr-7-163] Traditionally, successful pain management was defined as the achievement of analgesia without excessive adverse drug reactions; adverse effects often lead patients to discontinue their therapy[@b14-jpr-7-163],[@b15-jpr-7-163] and to express their dissatisfaction with pain treatment.[@b3-jpr-7-163],[@b16-jpr-7-163] However, other studies[@b17-jpr-7-163],[@b18-jpr-7-163] have reported high satisfaction ratings despite significant pain levels (the "pain paradox").[@b17-jpr-7-163] Psychosocial functioning and medical care management also influence patient satisfaction.[@b19-jpr-7-163]--[@b21-jpr-7-163] Our understanding of the factors influencing patient satisfaction is restricted by the fact that, to our knowledge, only two studies[@b22-jpr-7-163],[@b23-jpr-7-163] have drawn a comprehensive picture of the pharmacotherapeutic management of CNCP in primary care, including biopsychosocial and medical care characteristics.

We constituted a large cohort of primary-care patients from Quebec (Canada) suffering from CNCP. We used the data from this cohort to: 1) describe the pharmacotherapeutic pain management of these cohort patients; 2) assess their satisfaction with pain treatment; and 3) identify the determinants of their satisfaction. Community pharmacists may play a pivotal role in the management of pain therapy: they are highly accessible and well trained, and recent legislative changes in Quebec and Canada allow them to expand their scope of practice. Our results will therefore be discussed from a community pharmacy point of view.

Methods
=======

Study design
------------

As part of the ACCORD Program (Application Concertée des Connaissances et Ressources en Douleur), a knowledge translation research program in the field of CNCP, a cohort study was conducted.[@b24-jpr-7-163] Patients with CNCP having an active analgesic prescription from a primary-care physician were recruited in community pharmacies randomly selected in Quebec. Patients completed a telephone interview and a self-administered questionnaire. Prescribed medications delivered during the year preceding recruitment were documented using the administrative database of the Régie de l'assurance maladie du Québec (RAMQ) or the pharmacies' charts. Ethics approval was obtained from the Comité scientifique et d'éthique de la recherche of the Centre de santé et de services sociaux de Laval. Patients signed an informed consent form. Pharmacists received CAD \$50 for each consenting patient, and patients received \$25 if they completed the questionnaire.

Study population
----------------

The study was conducted on the territory of the Réseau universitaire intégré de santé of the Université de Montréal, which comprises six regions accounting for 40% of Quebec's population: Mauricie et Centre du Québec; Laval; Montréal; Laurentides; Lanaudière; and Montérégie. Using the Quebec Health Ministry's Atlas, we identified 513 community pharmacies. A random sampling stratified by region and weighted by the number of pharmacies within each region was performed to recruit a total of 60 pharmacies. Each participating pharmacy was asked to identify between 10 and 15 consecutive potentially eligible patients. To compensate for pharmacies that did not recruit the expected number of patients, additional pharmacies were invited to participate during the course of the study.

Patients were deemed eligible if they fulfilled the following criteria: 1) aged at least 18 years; 2) suffering from CNCP, defined as pain lasting for 6 months or more and not related to cancer; 3) reporting an average pain intensity in the past 7 days of at least 4 on a 0--10 intensity scale where 0 means "no pain" and 10 means "worst possible pain"; 4) suffering from pain at least 2 days a week; 5) able to speak and read French or English; and 6) having an active prescription from a primary-care physician for at least one of the following classes of analgesics: acetaminophen, nonsteroidal anti-inflammatory drugs, anticonvulsants, antidepressants, muscle relaxants, and opioids. We did not include patients treated solely with over-the-counter (OTC) analgesics (eg, acetaminophen). However, considering that when these medications are prescribed by a physician they are reimbursed by public or private drug insurance programs, we may have excluded only a small proportion of the target population. Patients who had migraine as the sole cause of pain were excluded, as were patients with any health problem that might prevent them from providing informed consent.

Procedure and measurement tools
-------------------------------

### Pain characteristics

In the telephone interview, patients rated their average and worst pain intensity over the past 7 days, and their current pain intensity using a 0--10 numerical intensity-scale, where 0 means "no pain" and 10 "worst possible pain." They reported time since initial onset of pain and frequency of pain in the past week ("always", "occasionally", "never"). To document sites and causes of pain, patients were asked: "Where do you usually have pain?" and "I will read a list of diagnoses that can be at the cause of your pain. Please, stop me each time I name a diagnosis corresponding to your condition."

### Psychosocial characteristics

Impact of pain on daily functioning was assessed in the telephone interview using the ten interference items of the modified Brief Pain Inventory (BPI). The BPI is a widely used instrument in pain research and its psychometric qualities are well documented.[@b25-jpr-7-163],[@b26-jpr-7-163] For each item, patients were asked to rate on a 0--10 intensity scale (0= does not interfere, 10= interferes completely) the extent to which pain interferes with their general activity, walking ability, mood, normal work, relations with other people, sleep, enjoyment of life, self-care, recreational activities, and social activities. A global BPI score is the average rating on the ten items.[@b25-jpr-7-163]

Impact of pain on sleep was documented with the Chronic Pain Sleep Inventory[@b27-jpr-7-163] during the telephone interview. A sleep problems index score is the mean of items 1, 3, and 4.[@b27-jpr-7-163] Scores range from 0--10. The higher the score, the worse the quality of sleep. Internal consistency reliability of the single sleep problems index is good (\>0.90).[@b27-jpr-7-163] We translated the original English version into French using a forward--backward procedure.

The Hospital Anxiety and Depression Scale[@b28-jpr-7-163] was included in the self-administered questionnaire. Scores ranged from 0--21. Depression and anxiety were rated as "absent" (≤7), "uncertain" (8--10), or "probable" (≥11).[@b28-jpr-7-163] This scale was validated for primary-care patients[@b29-jpr-7-163] and patients with chronic pain.[@b30-jpr-7-163]

The Barriers Questionnaire II,[@b31-jpr-7-163] included in the self-administered questionnaire, comprises 27 items grouped into four subscales (physiological effects, fatalism, communication, harmful effects). Mean scores for the total scale and subscales were computed. A higher score suggests a greater barrier to pain treatment. The questionnaire has high internal consistency (reliability coefficients ranging from 0.86--0.89).[@b31-jpr-7-163] Because it was designed for patients suffering from cancer pain, some of the items were adapted for this study. It was translated to French using a forward--backward procedure.

### Analgesics use

Analgesics use in the year preceding recruitment was documented for each patient using either the RAMQ database or the pharmacies' charts. Using pharmacies' charts was important to obtain information on patients not insured by the RAMQ for their prescription drugs. Antidepressants and anticonvulsants considered were those recommended for pain treatment[@b32-jpr-7-163],[@b33-jpr-7-163] and were documented only for patients not reporting epilepsy or depression, respectively, as an answer to the following telephone interview question: "I will read a list of health problems. Please stop me each time I name a health problem you have". Medications used to treat the cause of pain were not considered (eg, disease-modifying antirheumatic drugs). Patients reported their use of nonprescription analgesics by answering the following question: "In the past 6 months, have you taken OTC medications or natural products for pain?" The number of prescribers (all specialists and primary-care physicians), and the number and types of analgesics dispensed were documented.

### Adverse effects associated with analgesics

Adverse effects were documented using the following question in the self-administered questionnaire: "Because of your pain medication, how much were you bothered by the following gastrointestinal side effects -- constipation, stomach aches and/or heartburn, nausea and/or vomiting?" Severity was rated using a six-point Likert scale ranging from 0 ("not experienced") to 5 ("extremely bothered").[@b13-jpr-7-163] Scores of 1--2 were considered as mild and scores of 3--5 as moderate to severe. The medications prescribed to prevent or treat gastrointestinal adverse effects were documented using the pharmacies' charts or RAMQ database; OTC medications were documented during the telephone interview through such questions as: "In the past 6 months, have you taken OTC medications or natural products for constipation?" with similar questions for heartburn and nausea/vomiting. Information on laxatives, acid suppressants and gastroprotectants, and antiemetic therapies were collected.

### Patients' satisfaction with pain treatment

The Pain Treatment Satisfaction Scale (PTSS)[@b13-jpr-7-163] was included in the self-administered questionnaire. Each item is scored on a five-point Likert scale ranging from 1--5. Each subscale score was calculated using the mean of items related to the same domain according to Evans et al.[@b13-jpr-7-163] Scores were thereafter transformed into a 0--100 scale; higher scores indicated greater satisfaction. Overall patient satisfaction score was reported by computing the mean of the different domains scores. This questionnaire demonstrated internal consistency reliability coefficients ranging from 0.83--0.92.[@b13-jpr-7-163] We used a forward--backward process to translate it into French. Cronbach coefficients for the French version were similar to the original version, ranging from 0.70--0.91.[@b34-jpr-7-163]

Data analyses
-------------

For each psychosocial scale and satisfaction scale, overall and subscale scores were computed if patients answered more than 50% of items. To assess prevalence of use of each class of analgesic, patients who had at least one analgesic dispensed within the year preceding recruitment were considered as users. Patients who were dispensed at least one prescribed medication likely to treat a gastrointestinal adverse effect of analgesics and those reporting taking an OTC drug for management of gastrointestinal problems related to pain medication were considered as being treated for an adverse event.

To explore the determinants of patient satisfaction, multivariate linear regression models were developed. In each model, the overall PTSS satisfaction score and each PTSS subscale score was considered as the dependent variable. Independent variables were patients' characteristics (including psychosocial characteristics), medical care (eg, number of analgesic prescribers, number of physicians visits), and pharmacotherapy. They were all included in a multivariate model. Thereafter, using a backward selection process, the final models were defined using a type 1 error of 0.05 as the threshold of statistical significance. Statistical analyses were performed with SPSS software, version 19.0 (IBM Corporation, Armonk, NY, USA) and SAS software, version 9.1 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Between May and October 2009, 296 community pharmacies were randomly selected to participate in the study; 70 of them (23.7%) accepted and recruited patients ([Figure 1](#f1-jpr-7-163){ref-type="fig"}). From May 2009 to January 2010, pharmacists referred 609 patients; 38 patients were ineligible and 85 patients refused to take part. On average, each pharmacy recruited seven patients (range, 1--17 patients). The telephone interview, the self-administered questionnaire, and the documentation of prescribed analgesics were completed for 485, 483, and 486 patients, respectively.

Patients' biopsychosocial characteristics
-----------------------------------------

As reported in [Table 1](#t1-jpr-7-163){ref-type="table"}, patients' mean age was 58.4 (standard deviation \[SD\] =12.5) and women accounted for 67.7% of participants. About 54% were married or in a common-law relationship, and almost 70% were either unemployed, retired, or on temporary or permanent disability.

Patients reported a mean time since initial onset of pain of 11.7 years ([Table 2](#t2-jpr-7-163){ref-type="table"}). Nearly 75% of patients declared having suffered from continuous pain in the past 7 days. On a 0--10 intensity scale, average pain intensity reported on the past 7 days was 6.5 (SD =1.9), and worst pain intensity was 8.1 (SD =1.8). The most frequently reported pain sites were legs, thighs, knees (64.6%) and back (63.6%). In fact, 82.1% of patients reported more than one pain site (not reported in table). Most common patient-reported diagnoses were osteoarthritis and other osteopathologies (69.3%) and chronic back pain (60.1%). About one in four patients (23.5%) reported suffering from fibromyalgia, and 17.5% reported neuropathic pain.

BPI (impact of pain on daily living) and sleep quality scores were around 5 on 0--10 scales. Probable depression was identified in 23.9% of patients and anxiety in 39.9%. The greatest patients' barriers to optimal pain treatment were fear of the potential harmful effects of analgesics (3.1; SD =1.3) and the perception that nothing can be done to treat CNCP better (3.0; SD =1.2\]).

The overall pain treatment satisfaction score was 64.7 (95% CI =63.5--65.9) on a 0--100 scale. Subscale scores ranged from 50.6--74.0. Lowest scores were observed on the "information about pain and its treatment" subscale (50.6; 95% CI =47.6--53.7) and the "efficacy" subscale (53.6; 95% CI =51.5--55.6).

Pain pharmacotherapy
--------------------

By design, all study patients had at least one analgesic prescribed by a primary-care physician dispensed in the year preceding recruitment ([Table 3](#t3-jpr-7-163){ref-type="table"}). About half (52.8%) had analgesic prescriptions from two or more primary-care physicians and 39.7% had prescriptions from a pain specialist. In a year, on average, patients had prescribed analgesics dispensed on 22.4 different occasions (SD =26.1) with a median of 16 different occasions (not reported in table). Patients received a mean 4.2 different analgesics (range, 1--13 analgesics), and 23.3% received at least six different analgesics. The most prevalent classes of drugs used were nonsteroidal anti-inflammatory drugs (72.0% of cohort patients), opioids (65.6%), anticonvulsants (60.7%), and antidepressants (49.8%). Pregabalin was dispensed to 42.8% of patients (not reported in table). A total of 40.8% reported having used OTC medications and natural products in the previous 6 months. The most commonly used OTC product for pain relief was acetaminophen (used by 24.5%). Overall, 45.9% of patients either had prescribed acetaminophen dispensed or reported using OTC medications (not reported in table).

The prevalence of gastrointestinal adverse effects attributed by patients to analgesics is reported in [Table 3](#t3-jpr-7-163){ref-type="table"}. The proportions of patients under treatment for the relief of these adverse effects were also documented (not reported in table). Among patients with constipation, the proportion of those who had prescribed laxatives dispensed was low (mild symptoms =26.8%; moderate to severe symptoms =36.8%) as was the proportion of patients who reported using OTC medications (mild symptoms =27.5%; moderate to severe =40.6%). A similar result was reported among patients having moderate to severe nausea and vomiting (prescribed antiemetic =38.7%, OTC medication =19.4%). Overall, 61.3% of these patients were not taking prescribed antiemetics. Prescribed acid suppressants and gastroprotectants were commonly dispensed to patients reporting heartburn and stomach aches (mild symptoms =52.6%; moderate to severe =71.3%). However, 18.9% of patients reporting moderate to severe stomach aches/heartburn did not use either prescribed or OTC medications to relieve their symptoms. Overall, although 90% reported adverse gastrointestinal effects, 36.4% and 54.4% of these patients took no OTC or prescribed medication for constipation or nausea, respectively.

Determinants of patients' satisfaction with pain treatment
----------------------------------------------------------

As reported in [Table 4](#t4-jpr-7-163){ref-type="table"}, in a multivariate model, the overall treatment satisfaction (overall PTSS score) was lower among patients reporting more pain disability (−1.2 for each additional point on the BPI scale), those with probable depression (−4.4 points when compared to those with possible or no depression) and probable anxiety (−4.4 points), as well as those reporting more barriers to pain treatment (−4.3 points). Use of OTC and suffering from moderate to severe nausea were also negatively correlated with overall treatment satisfaction. Together, they accounted for 33% of the overall treatment satisfaction variance. Characteristics not listed in [Table 4](#t4-jpr-7-163){ref-type="table"} were not statistically significant predictors of the overall score or any of the subscale scores. These included pain characteristics (intensity, frequency, number of sites), medical care characteristics (number of primary-care physicians prescribing analgesics, care by a pain specialist), and other pharmacotherapy characteristics (being an opioid user, opioid dosage, suffering from moderate to severe constipation or heartburn). Characteristics that influenced several treatment satisfaction subscales included pain disability as measured by the BPI, barriers to pain treatment, use of OTC analgesics, and suffering from moderate to severe nausea.

Discussion
==========

This unique cohort study provides a comprehensive assessment of 486 primary-care patients suffering from uncontrolled CNCP. These patients had pain for more than a decade with significant disability and a high prevalence of probable depression and anxiety. On average, they were unconvinced that chronic pain can be adequately relieved and had concerns about the potential harmful addictive effects of analgesics. Prevalence of adverse gastrointestinal effects was high and, for the most part, left untreated by prescription or OTC drugs. Unsurprisingly, patients' satisfaction with pain treatment was negatively correlated with high pain disability, barriers about pain treatment, depression, anxiety, use of OTC pain relievers, and suffering from moderate to severe nausea. All primary-care clinicians involved in the management of CNCP should be concerned by these results. However, considering the frequency at which community pharmacists saw these patients (mean of 22.4 visits per year) as well as the expansion of their scope of practice, from a pharmacist's point of view, several lessons may be drawn from this survey.

To evaluate the effectiveness of a pain treatment, monitoring pain relief is not enough; treatment satisfaction is more closely associated with pain disability. Others have also reported a weak relationship between pain severity and patient satisfaction.[@b17-jpr-7-163],[@b18-jpr-7-163] For most patients with CNCP, aiming at a complete cure is often not an option.[@b35-jpr-7-163] However, attenuating the impact of pain on daily life is possible and important for patients.[@b36-jpr-7-163] Patients are usually dissatisfied by their treatment when their expectations are not met,[@b37-jpr-7-163],[@b38-jpr-7-163] which highlights the importance of establishing realistic and achievable goals.[@b38-jpr-7-163] In this regard, our results suggest that pain disability needs to be considered when defining treatment objectives. Pharmacists may help patients in setting their own treatment objectives and adjusting their pharmacotherapy appropriately by monitoring their pain disability. This could be done using the BPI.[@b25-jpr-7-163]

Emotional wellbeing was also associated with patient satisfaction. Others have reported similar associations,[@b12-jpr-7-163],[@b18-jpr-7-163],[@b39-jpr-7-163] and several studies suggest that psychological interventions can improve pain and disability.[@b20-jpr-7-163],[@b21-jpr-7-163],[@b40-jpr-7-163] Kroenke et al[@b21-jpr-7-163] showed that optimized antidepressant therapy coupled with a pain self-management program in primary-care patients with chronic musculoskeletal pain and comorbid depression resulted in moderate reductions in both pain severity and pain-related disability. Pharmacists should not hesitate to refer patients to their physicians and psychologists for appropriate treatment when needed. They may also play a pivotal role in optimizing antidepressant treatment by improving adherence to and persistence with treatment.

Patients with CNCP need to be better informed and educated regarding chronic pain and its management, the area where patients were most dissatisfied with their pain treatment. Furthermore, patients' concerns about the potential harmful addictive effects of analgesics use may compromise the effectiveness of their treatment.[@b41-jpr-7-163] Misconceptions and misunderstandings about pain therapeutics play an important role in the suboptimal management of pain.[@b42-jpr-7-163] Patient perceptions of the completeness and appropriateness of treatment can enhance motivation and compliance with treatment and may be a strong predictor of treatment and care satisfaction.[@b12-jpr-7-163],[@b43-jpr-7-163] According to Main et al,[@b43-jpr-7-163] patient beliefs are "a core part of pain perception" and influence response to treatment. Pharmacists can provide information about treatment and discuss barriers, beliefs, and attitudes about pain and its treatment. A few studies have evaluated the impact of pharmacists' educational interventions towards patients with chronic pain and shown positive results on the incidence of adverse events and improvement in patient satisfaction.[@b44-jpr-7-163] However, the impact of pharmacists' interventions on patients' barriers, beliefs, and attitudes about pain treatment remains to be evaluated.

The adverse effects of analgesics may limit effectiveness of treatment and decrease treatment satisfaction.[@b41-jpr-7-163] In our study, the prevalence of adverse gastrointestinal effects attributed to analgesics was high and was often left untreated by either prescription or OTC drugs. Similarly, Williams et al[@b22-jpr-7-163] showed that only 30% of Quebecers who were dispensed an opioid in 2005 were also dispensed medications to prevent gastrointestinal adverse effects. In the Netherlands, a study showed that only 37% of patients receiving a first prescription for a strong opioid also began to take a laxative within 5 days of starting therapy.[@b45-jpr-7-163] The exploratory trial by Bruhn et al[@b46-jpr-7-163] suggests that pharmacist medication review with or without face-to-face pharmacist prescribing may be beneficial for patients with chronic pain in terms of pain intensity and mental well-being. In Quebec, collective prescriptions could easily be implemented to allow pharmacists to appropriately prevent or relieve gastrointestinal adverse effects of analgesics treatment. Collective prescriptions are written and approved by a group of clinicians, including physicians and health authorities. They allow nurses and/or pharmacists to perform clinical tasks that normally fall outside their scope of practice (eg, prescribing medication).[@b47-jpr-7-163] Collective prescriptions are essential to allow pharmacists to play a more active role to ensure the effectiveness of, safety of, and adherence to analgesic treatment.

Strengths and limitations
-------------------------

The study was designed to increase external validity: recruitment in pharmacies facilitated the inclusion of patients followed by a relatively high number of primary-care physicians, a formal sampling frame of pharmacies was defined, and the random selection of pharmacies was stratified and weighted by region. On the other hand, pharmacy participation rate was low (23.6%). We had no information about patients who decided not to fill their analgesic prescription and patients taking only OTC analgesics. Our conclusions can only be generalized to CNCP patients receiving active treatment from a primary-care physician.

The internal validity of our results is high considering that the response rates for the self-administered and telephone questionnaires were very high and we were able to document the pharmacotherapy of all patients using two reliable sources of information. However, it is important to emphasize that all pain diagnoses, analgesic side effects, and OTC medication use were self-reported by patients. Moreover, pharmacotherapy was described using dispensed drugs; we have no information regarding their actual intake by patients. Also, we do not know what the indication for each prescription was. Although we only documented antidepressants and neuroleptics use among patients not reporting depression or epilepsy, respectively, we may have overestimated their prevalence of use as pain relievers.

Conclusion
==========

This study underlines how the expanded scope of practice of community pharmacists may allow them to play a pivotal role in the pharmacotherapeutic management of these patients by providing information, discussing barriers, beliefs, and attitudes about pain and its treatment, and monitoring pain disability, and by appropriately managing pharmacotherapy to optimize effectiveness while minimizing adverse effects.
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![Recruitment of pharmacies and patients.\
**Notes:** \*Pharmacy distribution per region (number of recruited pharmacies/total number per region): Mauricie et Centre du Québec: 6/60 (10%); Montréal: 18/134 (13.4%); Laval: 13/70 (18.5%); Lanaudière: 8/77 (13%); Laurentides: 14/95 (14.7%); Montérégie: 11/77 (14.3%); \*\*patients distribution per region (number of recruited patients per region/total number of patients): Mauricie et Centre du Québec: 44/486 (9%); Montréal: 92/486 (18.9%); Laval: 67/486 (13.8%); Lanaudière: 91/486 (18.7%); Laurentides: 117/486 (24.1%); Montérégie: 75/486 (15.4%).\
**Abbreviations:** n, number; RAMQ, Régie de l'assurance maladie du Québec.](jpr-7-163Fig1){#f1-jpr-7-163}

###### 

Demographic characteristics of patients

  Characteristics                                    n=486 (%)[\*](#tfn1-jpr-7-163){ref-type="table-fn"}
  -------------------------------------------------- -----------------------------------------------------
  Age (years), mean (SD)                             58.4 (12.5)
   65-years-old and older                            145 (29.8)
   Under 65 years old                                341 (70.2)
  Sex, women                                         329 (67.7)
  Mother tongue                                      
   French                                            437 (89.9)
   English                                           24 (4.9)
  Highest level of education completed               
   None or elementary school                         132 (27.2)
   Secondary school                                  170 (35.0)
   College technical school or university            177 (36.4)
  Civil status                                       
   Single                                            64 (13.2)
   Married or common-law relationship                263 (54.1)
   Separated or divorced                             98 (20.2)
   Widowed                                           57 (11.7)
  Current work                                       
   Full-time job                                     94 (19.3)
   Part-time job                                     27 (5.6)
   Retired                                           171 (35.2)
   Temporary or permanent disability                 100 (20.6)
   Unemployed                                        66 (13.6)
   Other                                             28 (5.8)
  Annual family income before income tax deduction   
   \<\$20,000                                        128 (26.3)
   \$20,000--\$50,000                                188 (38.7)
   \>\$50,000                                        117 (24.1)
  Main source of income                              
   Employment wages or salary                        155 (31.9)
   Retirement pension                                151 (31.1)
   Disability benefits                               86 (17.7)
   Social assistance                                 39 (8.0)
   Personal savings or family member                 55 (11.3)

**Notes:**

Unless otherwise indicated. Currency is Canadian dollars (CAD).

**Abbreviations:** n, number; SD, standard deviation.

###### 

Biopsychosocial characteristics of patients

  Characteristics                                                                                  n=486 (%)[\*](#tfn3-jpr-7-163){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------ -----------------------------------------------------
  Pain duration (years),[\*\*](#tfn4-jpr-7-163){ref-type="table-fn"} mean (SD)                     11.7 (11.1)
  Frequency of pain in the past 7 days                                                             
   Always                                                                                          363 (74.7)
   Occasionally                                                                                    116 (23.9)
   Never                                                                                           4 (0.8)
  Average pain intensity in the past 7 days,[‡](#tfn5-jpr-7-163){ref-type="table-fn"} mean (SD)    6.5 (1.9)
  Worst pain intensity in the past 7 days,[\*\*](#tfn4-jpr-7-163){ref-type="table-fn"} mean (SD)   8.1 (1.8)
  Current pain intensity,[‡](#tfn5-jpr-7-163){ref-type="table-fn"} mean (SD)                       5.4 (2.5)
  Sites of pain as reported by patients[§](#tfn6-jpr-7-163){ref-type="table-fn"}                   
   Legs, thighs, knees                                                                             314 (64.6)
   Back                                                                                            309 (63.6)
   Shoulders and/or arms                                                                           252 (51.9)
   Head and/or neck                                                                                209 (43.0)
   Chest and/or abdomen                                                                            134 (27.6)
   Hips                                                                                            114 (23.5)
  Pain diagnoses as reported by patients[§](#tfn6-jpr-7-163){ref-type="table-fn"}                  
   Osteoarthritis and other osteopathologies                                                       337 (69.3)
   Chronic back pain                                                                               292 (60.1)
   Chronic neck pain                                                                               185 (38.1)
   Fibromyalgia                                                                                    114 (23.5)
   Tendinitis, bursitis, capsulitis, epicondylitis                                                 98 (20.2)
   Neuropathic pain[‖](#tfn7-jpr-7-163){ref-type="table-fn"}                                       85 (17.5)
  Pain related interference (BPI), mean (SD)                                                       5.3 (2.2)
  Pain sleep impact (CPSI), mean (SD)                                                              5.1 (2.9)
  Level of depression (HADS)                                                                       
   Absent                                                                                          254 (52.3)
   Uncertain                                                                                       115 (23.7)
   Probable                                                                                        116 (23.9)
  Level of anxiety (HADS)                                                                          
   Absent                                                                                          176 (36.2)
   Uncertain                                                                                       115 (23.7)
   Probable                                                                                        194 (39.9)
  Barriers, prejudices and beliefs of patients (BQ-II), mean (SD)                                  2.6 (0.7)
   Physiological effects, mean (SD)                                                                2.5 (0.8)
   Fatalism, mean (SD)                                                                             3.0 (1.2)
   Communication, mean (SD)                                                                        2.2 (1.2)
   Harmful effects, mean (SD)                                                                      3.1 (1.3)
  Pain Treatment Satisfaction Scale (PTSS), mean (95% CI)                                          64.7 (63.5--65.9)
   Satisfaction with current pain medication                                                       62.5 (60.8--64.1)
   Medication characteristics subscale                                                             71.3 (69.5--73.0)
   Efficacy subscale                                                                               53.6 (51.5--55.6)
   Medical care                                                                                    67.9 (66.3--69.5)
   Impact of current pain medication                                                               58.0 (55.9--60.0)
   Information about pain and its treatment                                                        50.6 (47.6--53.7)
   Side effects of medication                                                                      74.0 (72.4--75.6)

**Notes:**

Unless otherwise indicated;

data missing for three patients;

data missing for four patients;

patient may report more than one site of pain;

neuropathic pain includes diabetic neuropathies, postherpetic neuralgia, and traumatic neuropathies.

**Abbreviations:** BPI, modified Brief Pain Inventory; BQ-II, Barriers Questionnaire II; CI, confidence interval; CPSI, Chronic Pain Sleep Inventory; HADS, Hospital Anxiety and Depression Scale; n, number; PTSS, Pain Treatment Satisfaction Scale; SD, standard deviation.

###### 

Pharmacotherapy in the past year

                                                                                                                             n=486 (%)[\*](#tfn9-jpr-7-163){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Type of analgesic prescribers[\*\*](#tfn10-jpr-7-163){ref-type="table-fn"}                                                 
   Primary-care physician                                                                                                    486 (100.0)
   Specialist                                                                                                                193 (39.7)
    Orthopedic surgeon                                                                                                       35 (7.2)
    Neurologist or neurosurgeon                                                                                              32 (6.6)
    Psychiatrist                                                                                                             29 (6.0)
    Rheumatologist                                                                                                           28 (5.8)
    Specialist in physical medicine and rehabilitation                                                                       20 (4.1)
    Anaesthesiologist                                                                                                        13 (2.7)
  Number of primary-care physicians analgesics prescribers per patient                                                       
   1 primary-care physician                                                                                                  229 (47.1)
   2 primary-care physicians                                                                                                 146 (30.0)
   3 or more primary-care physicians                                                                                         111 (22.8)
   Number of pharmacy visits to acquire analgesics, mean (SD)                                                                22.4 (26.1)
  Number of dispensed analgesics, mean (SD)                                                                                  4.2 (2.2)
   1--2 analgesics                                                                                                           118 (24.3)
   3--5 analgesics                                                                                                           255 (52.5)
   6 or more analgesics                                                                                                      113 (23.3)
  Prevalence by class of analgesic dispensed[\*\*](#tfn10-jpr-7-163){ref-type="table-fn"}                                    
   Nonsteroidal anti-inflammatory drugs                                                                                      350 (72.0)
   Opioids                                                                                                                   319 (65.6)
   Anticonvulsants                                                                                                           295 (60.7)
   Antidepressants                                                                                                           242 (49.8)
   Acetaminophen                                                                                                             138 (28.4)
   Muscle relaxants                                                                                                          126 (25.9)
  Prevalence of use of OTC analgesics[‡](#tfn11-jpr-7-163){ref-type="table-fn"},[§](#tfn12-jpr-7-163){ref-type="table-fn"}   197 (40.8)
  Prevalence of most often used OTC analgesics[‡](#tfn11-jpr-7-163){ref-type="table-fn"}                                     
   Acetaminophen                                                                                                             119 (24.5)
   Ibuprofen                                                                                                                 43 (8.8)
   Glucosamine                                                                                                               32 (6.6)
   Collagen                                                                                                                  17 (3.5)
  Prevalence of constipation                                                                                                 
   Not experienced                                                                                                           124 (25.5)
   Mild                                                                                                                      138 (28.4)
   Moderate to severe                                                                                                        220 (45.3)
  Prevalence of nausea and vomiting                                                                                          
   Not experienced                                                                                                           219 (45.1)
   Mild                                                                                                                      170 (35.0)
   Moderate to severe                                                                                                        93 (19.1)
  Prevalence of heartburn and stomach aches                                                                                  
   Not experienced                                                                                                           165 (34.0)
   Mild                                                                                                                      156 (32.1)
   Moderate to severe                                                                                                        164 (33.7)

**Notes:**

Unless otherwise indicated;

more than one answer possible;

prevalence for past 6 months;

data missing for three patients.

**Abbreviations:** n, number; OTC, over-the-counter; SD, standard deviation.

###### 

Clinical, psychosocial, medical care and pharmacotherapeutic characteristics associated with pain treatment satisfaction

                                         Pain Treatment Satisfaction Scale                                                                                                                                                                                                                                                                                                                                     
  -------------------------------------- --------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  Intercept                              88.0                                                79.7                                              75.6                                              86.7                                              84.8                                              80.5                                                 88.7                                                 97.9
  **Clinical characteristics**                                                                                                                                                                                                                                                                                                                                                                                 
  Duration of pain                                                                                                                                                                                                                                                                                                                                                                                             
   Each additional year of pain                                                                                                                0.23[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                                                                       0.40[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}                                                         
  Frequency of pain                                                                                                                                                                                                                                                                                                                                                                                            
   Continuous                                                                                −5.6[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −8.2[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                                                                       −8.0[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                           
   Occasional                                                                                Reference                                         Reference                                                                                                                                             Reference                                                                                                 
  Number of pain sites                                                                                                                                                                                                                                                                                                                                                                                         
   Each additional site                                                                                                                        −1.5[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                                                                       −1.5[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                           
  **Psychological characteristics**                                                                                                                                                                                                                                                                                                                                                                            
  Pain disability (BPI)                                                                                                                                                                                                                                                                                                                                                                                        
   Each additional point (0--10 scale)   −1.2[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}   −1.2[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −1.6[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                                                                                                                            −1.8[\*](#tfn14-jpr-7-163){ref-type="table-fn"}      −1.0[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}
  Pain sleep impact (CPSI)                                                                                                                                                                                                                                                                                                                                                                                     
   Each additional point (0--10 scale)                                                                                                                                                                                                                                                               −1.0[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                           
  Level of depression (HADS)                                                                                                                                                                                                                                                                                                                                                                                   
   Probable                              −4.4[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                                                                                                                                                                             −15.9[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}                                                        
   Other                                 Reference                                                                                                                                                                                                                                                   Reference                                                                                                 
  Level of anxiety (HADS)                                                                                                                                                                                                                                                                                                                                                                                      
   Probable                              −4.4[\*](#tfn14-jpr-7-163){ref-type="table-fn"}     −4.9[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                     −6.2[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −5.0[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −5.7[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                           −4.1
   Other                                 Reference                                           Reference                                                                                           Reference                                         Reference                                         Reference                                                                                                 Reference
  Barriers to pain treatment (BQ-II)                                                                                                                                                                                                                                                                                                                                                                           
   Each addition point (0--5 scale)      −4.3[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}                                                                                                       −4.4[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −4.2[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                        −10.1[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}   −2.0
  **Pharmacotherapy characteristics**                                                                                                                                                                                                                                                                                                                                                                          
  Use of OTC analgesics                                                                                                                                                                                                                                                                                                                                                                                        
   Yes                                   −4.9[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}   −5.3[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −5.4[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                     −5.6[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −5.5[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                           
   No                                    Reference                                           Reference                                         Reference                                                                                           Reference                                         Reference                                                                                                 
  Moderate to severe constipation                                                                                                                                                                                                                                                                                                                                                                              
   Yes                                                                                                                                                                                                                                                                                                                                                                                                         −9.7[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}
   No                                                                                                                                                                                                                                                                                                                                                                                                          Reference
  Moderate to severe heartburn                                                                                                                                                                                                                                                                                                                                                                                 
   Yes                                                                                                                                                                                                                                                                                                                                                                                                         −13.5[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}
   No                                                                                                                                                                                                                                                                                                                                                                                                          Reference
  Moderate to severe nausea                                                                                                                                                                                                                                                                                                                                                                                    
   Yes                                   −9.2[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}   −6.8[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −7.1[\*](#tfn14-jpr-7-163){ref-type="table-fn"}   −7.4[\*](#tfn14-jpr-7-163){ref-type="table-fn"}                                                     −7.6[\*](#tfn14-jpr-7-163){ref-type="table-fn"}      −10.3                                                −15.3[\*\*](#tfn15-jpr-7-163){ref-type="table-fn"}
   No                                    Reference                                           Reference                                         Reference                                         Reference                                                                                           Reference                                            Reference                                            Reference
  R^2^ of a multiple regression model    0.33                                                0.13                                              0.13                                              0.10                                              0.08                                              0.31                                                 0.09                                                 0.62

**Notes:**

α *P*\<0.05;

β *P*\<0.000l.

**Abbreviations:** BPI, Brief Pain Inventory; BQ-II, Barriers Questionnaire II; CPSI, Chronic Pain Sleep Inventory; HADS, Hospital Anxiety and Depression Scale; OTC, over-the-counter.
